In a nutshell This study evaluated the effectiveness and safety outcomes of atezolizumab (Tecentriq) given before surgery for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that atezolizumab given before surgery was safe and effective for patients with NSCLC. Some background Non-small cell lung cancer (NSCLC)...
Read More
In a nutshell This study evaluated the effectiveness and safety of high-dose rosuvastatin (Crestor) combined with telmisartan (Micardis) or amlodipine (Norvasc) on glucose metabolism in patients with atherosclerotic cardiovascular disease (ASCVD), hypertension (high blood pressure), and impaired fasting glucose (IFG or prediabetes). The...
Read More
In a nutshell This study evaluated the effectiveness and safety of busulfan (Bu; Busulfex) plus cyclophosphamide (Cy; Cytoxan) (BuCy) regimen versus total body irradiation (TBI) plus cyclophosphamide (TBI-Cy) regimen for patients with adult B-cell acute lymphoblastic leukemia (B-ALL) in first complete remission undergoing allogeneic hematopoietic...
Read More
In a nutshell The study compared the effectiveness of darolutamide (Nubeqa), apalutamide (Erleada), and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (nmCRPC). The data showed that darolutamide, apalutamide, and enzalutamide were similarly effective and improved survival outcomes compared to placebo...
Read More
In a nutshell This study evaluated the effectiveness and safety of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine in patients with breast and gynecological cancer. The data showed that most patients with breast and gynecological cancer developed antibodies after the second dose of the vaccine. However, the authors suggested that for non-responders or weak...
Read More
In a nutshell This study evaluated the effectiveness and safety of oral paclitaxel (Taxol) plus encequidar (HM 30181) versus intravenous (IV) paclitaxel in patients with metastatic breast cancer (BC). This study concluded that oral paclitaxel plus encequidar was more effective than IV paclitaxel with manageable side effects in these...
Read More
In a nutshell This study investigated the safety and effectiveness of different doses of asundexian (BAY 2433334) in patients with acute myocardial infarction (MI; heart attack) treated with dual antiplatelet therapy (DAPT). The data showed that asundexian 50 mg when added to DAPT inhibits blood clotting factor XIa by more than 90% without...
Read More
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) lead-in treatment before venetoclax (Venclexta) initiation for reducing tumor size in patients with chronic lymphocytic leukemia (CLL). The data showed that three cycles of ibrutinib lead-in treatment before venetoclax initiation significantly reduced the tumor...
Read More
In a nutshell This study evaluated the impact of fertility preservation with ovarian stimulation on breast cancer and pregnancy outcomes in young women with breast cancer (BC). The data showed that fertility preservation was safe and did impact BC outcomes. Some background Breast cancer (BC) is one of the most common cancers affecting women...
Read More
In a nutshell This study investigated the occurrence of osteoporosis (OP) in patients with rheumatoid arthritis (RA). The authors concluded that although significant advancements were made in OP prevention, treatment and diagnosis, a high occurrence was still observed in patients with RA. Some background OP commonly occurs in patients with RA. It...
Read More
In a nutshell This study compared intermittent scanning continuous glucose monitoring (isCGM) with real-time continuous glucose monitoring (rtCGM) for the treatment of type 1 diabetes (T1D). It found that compared to isCGM, rt CGM resulted in increased time spent in range and improved blood glucose control in these patients. Some background...
Read More
In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...
Read More
